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Patients with chronic congestive heart failure (CHF) 
are known to have elevated plasma concentrations 
of norepinephrine. Although this elevation of cate- 
cholamines in plasma may facilitate myocardial 
contractility, it may also be toxic to the myocardium 
in the long term. The alpha2 adrenoreceptor located 
on noradrenergic nerve terminals regulates neuronal 
norepinephrine release by feedback inhibition. This 
receptor is also located on human blood platelets. 
This study determines, the status of platelet alpha;! 
adrenoreceptors in 16 patients with CHF (class I and 
II in 7 and class Ill and IV in 9) and in 26 normal 
volunteers. Specific high-affinity binding of the 
alpha* agonist 3H-clonidine and the alpha* antag- 
onist 3H-yohimbine was used to determine the 
number (B,,,) of alpha* receptors and the disso- 
ciation constant (Ku) for the 2 ligands. In the control 
population, the B,,, (in fmol/mg protein) for 3H- 
clonidine was 33 f 2 and for 3H-yohimbine was 165 
f 12. There was a 25 % difference in the maximum 
number of specific binding sites for 3H-clonidine in 
the class III/IV group (B,,, 24 f 2, p X0.05) and a 
43 % difference in the maximum number of specific 
binding sites for 3H-yohimbine (B,,, 94 f 9; p 
<0.005). There was a smaller but nonsignificant 
difference in the number of receptors on platelets 
from patients in the class I and II group. The Ku’s 
were similar in all 3 groups. These differences cor- 
related well with the increases in plasma norepi- 
nephrine levels between the normal group (273.6 
f 44.1 pg/ml) and the class III/IV group (1333.5 
f 244.9, p <0.0005). This study supports the hy- 
pothesis that increased levels of circulating nor- 
epinephrine in CHF lead to a decrease in platelet 
alpha* adrenoreceptors. Further studies should be 
performed to determine whether pharmacologic 
stimulation of these receptors might lead to a de- 
crease in the neuronal release of that norepinephrine 
which might be toxic to the myocardium. Monitoring 
of platelet alpha* adrenoreceptor number may 
provide a guide to therapy of CHF. 
Patients with chronic congestive heart failure (CHF) 
are known to have elevated concentrations of circulating 
norepinephrine. The degree of elevation is related to the 
degree of left ventricular dysfunction.1-3 Although the 
circulating norepineph.rine may increase myocardial 
contractility, persistently elevated levels have been 
shown to be toxic to the myocardium in experimental 
animals4-6 and in humans.7,8 
The alphas adrenoreceptor is located presynaptically 
on noradrenergic nerve terminals and has been shown 
From the Departments of Pharmacology and Internal Medicine, Uni- 
versity of Michigan Medical School, Ann Arbor, Michigan. This study 
was supported in part by Grant MH-36226 from the U.S. Public Health 
Service, Bethesda, Maryland, and a grant from the Michigan Heart 
Association, Lathrup Village, Michigan. Manuscript received January 
17. 1983; revised manuscript received March 21.1983, accepted March 
25, 1983. 
Address for reprints: Charles B. Smith, MD. PhD, Department of 
Pharmacology, University of Michigan Medical School, Ann Arbor, 
Michigan 48109. 
to exert a negative feedback inhibition upon norepi- 
nephrine release when stimulated.g-’ l If neurogenically 
released norepinephrine has a detrimental effect on the 
myocardium, alterations in alphas adrenoreceptor 
function might be of potential importance in CHF. 
Human blood platelets have been suggested as a model 
for the indirect study of changes in nerve cell function.is 
Studies which use receptor binding techniques and 
which measure the relative order of potencies of various 
adrenergic agonists and antagonists in displacing bound 
radioligand have shown that human platelets have 
alphas adrenoreceptors similar to those present on 
noradrenergic nerve terminals.lsJ4 Changes in the 
number and affinity of alphas adrenoreceptor binding 
sites in the rat brain after various interventions have 
been well correlated with similar changes on human 
blood platelets.14-l7 These have also been correlated 
with changes in norepinephrine release and tension 
developed in field stimulation experiments upon iso- 
lated rat atria1 strips.18 
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The hypothesis of the present study was that alphas 
adrenoreceptors on human blood platelets would be 
decreased by the increased circulating levels of nor- 
epinephrine found in severe chronic CHF and as such 
mirror changes found in the presynaptic site. 
Methods 
Patient population: Blood was obtained by venipuncture 
from healthy male and female volunteers (mean age 40 f 3 
years, n = 26). These control subjects were compared with 
patients with chronic CHF who were selected and classified 
by history, physical examination, and invasive hemodynamic 
monitoring findings. The patients were divided into standard 
New York Heart Association19 class I and II (Group 1: mean 
age 62 f 2 years, n = 7) and class III and IV groups (Group 2: 
mean age 68 f 4 years, n = 9). The cause of the CHF was val- 
vular (Group 1 = 3, Group 2 = 2), ischemic (Group 1 = 3, 
Group 2 = 5), and idiopathic (Group 1 = 1, Group 2 = 2). The 
2 groups did not differ in the distribution of causes. Previous 
work16 has shown the lack of age or sex dependency of either 
the total number or the affinity of platelet alphas adrenore- 
ceptors. None of the patients were taking alpha-adrenergic 
agonists or antagonists, indirectly acting adrenergic drugs, or 
inhibitors of norepinephrine uptake for at least 1 month before 
the study. 
Written informed consent was obtained from all patients. 
This study was approved by the University of Michigan’s 




FfGURE 1. Specific binding of 31+clonidine to platelet membranes from 
normal subjects (solid line) and from patients with class Ill and IV 
congestive heart failure (dashed Ilne) as a function of increasing con- 
centrations (1 to 64 nM) of the ligand. Grdlnate, 3H-clonidine specifically 
bound (fmol/mg protein). Abscissa, concentration of %clonidine (r-M). 
Inset, Scatchard plot showing the change in number of the high affinity 
binding site (normal subjects: B,,,,, = 33 f 2 fmol/mg protein, Ko = 
5.5 f 0.6 nMversus class Ill and IV: B,,, = 24 f 2, Ko = 3.4 f 0.6 
nM p <0.05). Results are expressed as the mean f standard error of 
the mean. B = specifically bound ligand; B/F = specifically bound li- 
gand/free ligand. 
Institutional Review Board. All assays were done without the 
knowledge of the patient’s clinical characteristics. 
Isolation of platelet membranes and radioligand 
binding assay: Platelet membranes were obtained by the 
method described by Garcia-Sevilla et al.‘* Briefly, 50 ml of 
blood was collected in polyethylene tubes which contained 
acid-citrate dextrose (ACD, 81, volume/volume). The blood 
was centrifuged at 160 g for 10 minutes (25”C), and the 
platelet-rich plasma was titrated to pH 6.5 with the ACD so- 
lution. This was then recentrifuged at 5,lOOg for 15 minutes 
(25OC) to obtain a platelet pellet. The pellet was washed twice 
with 5 ml of Tyrode’s buffer (mit4 concentrations: sodium 
chloride 137, potassium chloride 2.7, sodium biphosphate 0.36, 
magnesium chloride 0.10, sodium bicarbonate 12.0, dextrose 
0.56, pH 8.0) and recentrifuged for 15 minutes at 5,100 g. The 
pellet was lysed by homogenization in 2 ml of ice-cold hypo- 
tonic buffer (Tris-EDTA, 5 mA4, pH 7.5). The platelet mem- 
branes were obtained by centrifugation at 39,000 g for 10 
minutes and then resuspended in the Tris incubation buffer 
(mM: Tris-hydrochloric acid 50, magnesium chloride 10, pH 
7.5) used in the binding assay. 
Total binding of 3H-clonidine, an alphaa-adrenoreceptor 
agonist, and of 3H-yohimbine, an alphaz-adrenoreceptor an- 
tagonist (New England Nuclear, Boston, Massachusetts) was 
measured in 1 ml aliquots of the fresh platelet membranes 
(0.254 f 0.054 mg protein) which were incubated in duplicate 
at 25OC for 20 minutes with the radioligand. Nonspecific 
binding was determined by adding unlabelled clonidine or 
yohimbine (10e5 M), in addition to the respective tritiated 
ligand, to a second pair of incubates. Specific binding was 
sH-YOHI&NE hM) 
._ 
FIGURE 2. Specific binding of 3H-yohimbine to platelet membranes 
from normal subjects (solld Ilne) and from patients with class Ill and IV 
congestive heart failure (dashed Ilne) as a function of increasing con- 
centrations (0.25 to 16 n&f) of the ligand. Ordinate, 3H-yohimbine 
specifically bound (fmol/mg protein). Abscissa, concentration of 3H- 
yohimbine (nkf). Inset, Scatchard plot showing the change in number 
of the single binding site (normal subjects: B,,, = 165 f 12 fmol/mg 
protein, Ko = 4.0 f 0.5 nMversus class Ill and IV: B,, = 94 i 9, K,-, 
= 4.4 f 0.4; p <0.005). Results are expressed as the mean f standard 
error of the mean. B = specifically bound ligand; B/F = specifically 
bound ligand/free ligand. 
defined as the difference between total and nonspecific 
binding. Incubations were .terminated by adding 5 ml of the 
Tris incubation buffer to the sample. The membrane-bound 
tritiated ligand was recovered by rapid filtration of the diluted 
sample under vacuum through Whatman GF/C glass fiber 
filters. The filters were washed with two 10 ml aliquots of Tris 
incubation buffer (25°C). The filters were air dried and 
counted for radioactivity a,3 described by Smith et a1.20 Pro- 
teins were determined by the method of Lowry et a1.21 
Catecholamine determination: Catecholamine deter- 
minations were performed by the radioenzymatic assay of 
Passon and Peuler.22 The rat liver catechol-O-methyltrans- 
ferase (COMT) was prepared according to the method of 
Axelrod and Tomchick. A.11 blood samples were collected as 
described above with the patient recumbent for at least 30 
minutes. The samples were immediately centrifuged and the 
serum was frozen at -70°C. 
Statistical analysis: Student’s t test was used to test for 
the significance of differences. The level of significance was 
p <0.05. Correlation coefficients for the binding isotherms 
were obtained by linear regression analysis which uses the 
method of least squares. 
Ftesults 
Binding data: The specific binding of both 3H-clo- 
nidine and 3H-yohimbine to platelet membranes from 
both normal subjects and patients with chronic CHF 
was both saturable and of high affinity (Fig. 1 and 2). 
Scatchard analysis of the saturation isotherms again 
confirmed previous obsNervations15 that there was no 
correlation between age or sex and the total number of 
binding sites (B,,,) or the affinity (KD) of the radioli- 
gand for the site. The individual data for the control 
population for 3H-clonidine (n = 26) was B,,, = 33 
f 2 and KD = 5.5 f 0.6, and for 3H-yohimbine (n = 16) 
was B,,, = 165 f 12, and KD = 4.0 f 0.5. There was no 
difference in the means for either ligand when the over 
60-year-old subgroup was compared with the under 
60-year-old group. 
Patients with the more severe CHF, class III and IV 
(n = 9, Table I) had a :25% decrease in the maximum 
number of 3H-clonidine binding sites compared with 
control subjects (B,,, = 24 f 2, p <0.05, Fig. 1) with no 
change in affinity (KD = 3.4 f 0.6, difference not sig- 
nificant). There was also a marked decrease in the B,,, 
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for 3H-yohimbine (43%, B,,, = 94 f 9, p cO.005) but 
no change in the affinity of the ligand for the receptor 
(KD = 4.4 f 0.4, Fig. 2). Patients with class I and II 
chronic CHF (n = 7, Table II) had binding data with 
3H-yohimbine that suggested a trend towards a de- 
crease in B,,, as compared with normal subjects (B,, 
= 133 f 16). This was not statistically significant. In this 
group, there were not enough studies done with 3H- 
clonidine to analyze. 
Plasma catecholamines: Plasma norepinephrine, 
epinephrine, and dopamine levels were measured in all 
control subjects and patients. In normal subjects, the 
norepinephrine value was 273.8 f 44.1 pg/ml (range 54 
to 503). There was a statistically significant increase in 
norepinephrine levels in patients with class I and II 
CHF (628.7 f 97.6 pg/ml, range 338 to 1079; p <0.005) 
with a far more significant increase in patients with class 
III and IV CHF (1333.5 f 244.9 pg/ml, range 642 to 
3142; p <0.0005). 
There was no significant difference in plasma epi- 
nephrine concentration between normal subjects and 
class I and II patients (normals 57.0 f 17.4 pg/ml, class 
I and II 95.0 f 48.7). Plasma epinephrine level was el- 
evated significantly in patients with class III and IV 
CHF (117.1 f 32.0, p <0.05). Although there was no 
significant difference in plasma dopamine concentration 
between the normal group (12.5 f 9.9 pg/ml) and the 
class I and II CHF group (38.5 f 19.6), there also was a 
statistically significant increase in the class III and IV 
group (94.1 f 31.1, p <O.Ol). 
There was a striking relationship for each group be- 
tween an elevated level of plasma norepinephrine and 
a decrease in the total number of binding sites for the 
tritiated ligand (Fig. 3). 
Discussion 
The 3H-clonidine binding site on human platelets has 
been characterized as an alphaz-adrenoreceptor site 
similar to that located presynaptically.13J4 Stimulation 
of alpha2 presynaptic receptors24*25 inhibits neuro- 
transmitter release during nerve stimulation, whereas 
inhibition of the site increases the overflow of norepi- 
nephrine after nerve stimulation. 
TABLE I 3H-Clonidine and 3H-Yohimbine Binding to Platelet Membranes of Patients With Congestive Heart Failure (Class 














K14 76M 1,133 2: 106 . . . . . 
K19 70F 1,122 
:: 
. . . . 
K21 60M 3,143 2.8 . . 
::2 65M 57 643 1 6:l 120 62 . . . . . 
C23 76F 1,397 4.2 109 i.4” :8’ 
C26 64M 1,329 6.3 93 3:2 26 
c31 76M 913 4.1 106 4.3 4 40F 1,5 0 3 9 8 5 Xt 
Mean 68.1 1,334 4.4 94 3.4 24 
fSEM f:3.a f245 f0.5 f9 f0.6 f2 
B max = maximum number of binding site (fmollmg protein); Ko = dissociation constant (n&f)); SEM = standard error of the mean. 
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TABLE II 3H-Clonidine and 3H-Yohimbine Binding to Platelet Membranes of Patients With Congestive Heart Failure (Class 
I and II) 













K12 70F a45 5.6 144 
K13 59F 1.079 6.0 157 
K18 56M 626 3.2 111 
K20 59F 604 2.5 192 . 
:: 
72F 499 3.0 109 . 
62M 338 6.2 113 
C32 65M 409 3.2 a4 26 24.6 
Mean 61.8 629 4.2 133 . 
fSEM f2.0 f9a f0.6 f16 
B max = maximum number of binding site (fmol/mg of protein); Ko = dissociation constant (nM); SEM = standard error of the mean. 
Although a recent review26 suggested that the number 
of alphas adrenoreceptors on human platelets as de- 
termined by 3H-yohimbine binding is not subject to 
down-regulation, data presented here suggest this is not 
the case. The total number of binding sites, B,,,, as 
defined by sH-yohimbine binding, was 43% less in the 
class III and IV CHF patients and 19% less in the class 
I and II patients as compared with normal subjects. This 
was statistically significant for the class III and IV pa- 
tients (p <0.0005). Changes of a similar magnitude were 
also noted using 3H-clonidine as the radioligand (class 
III and IV 25%, p <0.05). Other work from our labora- 
tory14 has shown significant increases in the number of 
platelet alpha2 adrenoreceptors in other settings, such 
as a group of depressed patients versus a normal control 
population. Treatment with tricyclic antidepressants14 
or with electroconvulsive shock therapy16 led to a sig- 
nificant decrease in the number of these binding sites. 
These changes are mirrored by changes in the presyn- 
aptic alpha2 adrenoreceptor in the rat brain after 




Ill - IV 
FIGURE 3. Relationship of plasma norepinephrine levels (open bars) 
and the maximum number of 3H-yohimbine (shaded bars) and 3H-clo- 
nidine (cross-hatched bars) binding sites. l p <0.05, * l p <0.005, 
*** p <0.0005 (between control group and group with class III/IV 
failure). NLS = normal subjects. 
changes in receptor number may not be of physiologic 
importance. 26 Again, work in our laboratory has corre- 
lated decreases in alphas-adrenoreceptor number in rat 
brain after long-term tricyclic antidepressant drug 
treatment18 with increased norepinephrine release from 
adrenergic neurons in the isolated rat left atrium.18 
Further evidence of the physiologic importance of this 
decrease in the number of presynaptic receptors in pa- 
tients with severe congestive failure may be found in the 
recent work by Swedberg et a1.27 They defined a corre- 
lation between myocardial norepinephrine release and 
the stroke work index. As left ventricular function de- 
creased, there was an increase in norepinephrine re- 
leased, as measured by the arterial-coronary sinus dif- 
ference. In our study, a decrease in left ventricular 
function was associated with fewer alphas adrenore- 
ceptors, a condition which would permit increased 
neuronal norepinephrine release. 
Older work by Cove11 et al,28 however, was interpreted 
as not suggesting increased neuronal release of norepi- 
nephrine in CHF. They showed that stimulation of the 
right cardio-accelerans nerve in the dog produced 
sharply diminished increases in heart rate and right 
ventricular contractile force in animals with right heart 
failure versus normal control animals. In addition, they 
showed that the myocardial response to exogenous 
norepinephrine was unchanged from normal values, 
which suggested to them that the quantity of neuro- 
transmitter released per nerve impulse was reduced in 
their experimental model of heart failure. That the 
cardiac norepinephrine depletion found in chronic CHF 
did not affect the contractile function of cardiac muscle 
was shown with cat papillary muscle isolated from 
chronically denervated heart2g and with isolated rat 
hearts.30 One would have, perhaps, expected increased 
release of norepinephrine with the decrease in number 
of platelet alphas adrenoreceptors. This inconsistency 
may possibly be explained by a decrease in cardiac 
stores of norepinephrine in CHF,a1-33 a defect in bind- 
ing or synthesis of catecholamines in congestive fail- 
ure,34 or by a decrease in tyrosine hydroxylase activity.35 
Although it is believed that the platelet alpha2 adre- 
noreceptor “down-regulates” in response to the high 
plasma concentrations of norepinephrine, it is possible 
that any similar change in the neuronal receptors in the 
July 1983 THE AMERICAN JOURNAL OF CARDIOLOGY Volume 52 105 
myocardium may occur in order to permit an increase 
in norepinephrine release. The increased release of 
catecholamine would permit increased inotropic sup- 
port of the failing myocardium. That different tissues 
may respond differently in CHF has been suggested by 
data which showed decreased myocardial norepineph- 
rine stores in light of normal renal stores.32 
In our study, there was a significant increase in 
plasma norepinephrine levels in patients with class III 
and IV CHF versus those of normal volunteers (p 
<0.0005) and also in those with only class I or II CHF 
(p <O.OOS). Although the blood samples were obtained 
by venipuncture and not through an indwelling cathe- 
ter, previous work suggests this does not affect the 
plasma norepinephrine ,concentration.36 These values 
are consistent with previously reported studies1,4p5 
which correlated an elevated plasma norepinephrine 
level with the degree of left ventricular dysfunction. 
There were no significa:nt differences in the levels of 
epinephrine and dopamine in the normal subjects and 
the class I/II group, although there was a difference in 
the levels of epinephrine (p <0.05) and dopamine (p 
<O.Ol) in the normal groups and the class III/IV 
group. 
This study suggests that in CHF, human platelet 
alpha2 adrenoreceptors may serve as a marker of ele- 
vated levels of circulating norepinephrine. Changes in 
the platelet receptor number may be a method of 
monitoring the therapy of congestive failure. Identifi- 
cation and characterization of these receptors suggest 
the possibility of using alphaz-agonist agents such as 
clonidine or alpha meth,yldopa to stimulate these in- 
hibitory sites and thus decrease norepinephrine release. 
This may, in turn, protect the myocardium from the 
excessively high levels of circulating norepinephrine as 
has been done with beta-adrenergic blockade. Further 
studies in humans are needed to ascertain whether 
successful therapy in patients with CHF restores the 
receptor number to nor:mal. These changes should be 
correlated in animal models of heart failure with neu- 
ronal release of norepinephrine after nerve stimulation. 
Such changes may prove important in developing new 
therapeutic strategies in the treatment of CHF. 
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